Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 1014

Prof Arnaud Mejean - Paris Descartes University, Paris, France

Prof Arnaud Mejean talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the update from the CARMENA trial, which is looking at cytoreductive nephrectomy (CN) in metastatic renal cancer, focusing on the intermediate IMDC-risk population.

He reports that trial confirms that CN is not superior to sunitinib alone in patients with metastatic kidney cancer with a longer follow up of 61.5 months.

Prof Mejean also reports that for patients with only one IMDC risk factor, CN might be beneficial.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation